Gender Difference in V2 Receptor Function in Response to dDAVP Infusion

0
Pipeline Programs
1
Companies
1
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

1 companies ranked by most advanced pipeline stage

Ferring Pharmaceuticals
Ferring PharmaceuticalsArgentina - Buenos Aires
1 program
dDAVP infusionN/A1 trial
Active Trials
NCT02068560Completed64Est. Dec 2014

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Ferring PharmaceuticalsdDAVP infusion

Clinical Trials (1)

Total enrollment: 64 patients across 1 trials

NCT02068560Ferring PharmaceuticalsdDAVP infusion

The Effect of Gender on Antidiuresis - Evaluated by Graded Low Dose Desmopressin Infusion

Start: May 2012Est. completion: Dec 201464 patients
N/ACompleted

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 companies competing in this space